1. Home
  2. RELY vs CELC Comparison

RELY vs CELC Comparison

Compare RELY & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Remitly Global Inc.

RELY

Remitly Global Inc.

HOLD

Current Price

$24.38

Market Cap

4.5B

Sector

Technology

ML Signal

HOLD

Logo Celcuity Inc.

CELC

Celcuity Inc.

BUY

Current Price

$58.06

Market Cap

4.2B

Sector

Health Care

ML Signal

BUY

Company Overview

Basic Information
Metric
RELY
CELC
Founded
2011
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Medical Specialities
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.5B
4.2B
IPO Year
2021
2017

Fundamental Metrics

Financial Performance
Metric
RELY
CELC
Price
$24.38
$58.06
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
10
12
Target Price
$32.11
★ $156.91
AVG Volume (30 Days)
★ 3.0M
1.3M
Earning Date
11-04-2026
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 263.16
N/A
EPS
★ 1.16
N/A
Revenue
★ $1,635,147,000.00
N/A
Revenue This Year
$21.52
N/A
Revenue Next Year
$19.42
$1,322.81
P/E Ratio
$20.83
★ N/A
Revenue Growth
★ 29.37
N/A
52 Week Low
$12.08
$53.54
52 Week High
$27.48
$151.02

Technical Indicators

Market Signals
Indicator
RELY
CELC
Relative Strength Index (RSI) 58.18 27.14
Support Level $22.54 N/A
Resistance Level $24.87 $118.53
Average True Range (ATR) 0.83 4.68
MACD 0.31 -1.06
Stochastic Oscillator 80.57 14.51

Price Performance

Historical Comparison
RELY
CELC

About RELY Remitly Global Inc.

Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. The company's revenue is generated from transaction fees charged to customers, and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.

About CELC Celcuity Inc.

Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.

Share on Social Networks: